# Nasdaq:RXRX news releases

Nasdaq:RXRX press releases distributed through HARO Newswire to the journalists who cover the beat.

- **Releases in the last 90 days:** 89
- **Web page:** https://www.helpareporter.com/news-releases/nasdaqrxrx
- **RSS:** https://www.helpareporter.com/news-releases/nasdaqrxrx/rss.xml

### [Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis](https://www.helpareporter.com/news-releases/recursion-announces-alignment-with-fda-on-registrational-phase-3-trial-2)

November 18, 2026 · Recursion · Nasdaq:RXRX

REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies.
